Social Behavior
BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion
BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology
BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront
BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
EU Upholds Approval of PTC Therapeutics’ Duchenne Muscular Dystrophy Treatment
EU, PTC Therapeutics, Duchenne Muscular Dystrophy (DMD), treatment, approval, rejection, committee.
FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer
FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data
FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection